AbbVie’s 8-week hepatitis C drug granted early access in UK
AbbVie’s hepatitis C drug granted early access in UK
AbbVie’s hepatitis C drug granted early access in UK
Examining the views of different stakeholders in the ecosystem supporting drug R&D.
The top 10 pharma milestones of the year to date.
Roche’s MS drug is among major drugs still to come in 2016.
Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
NOhep campaign supports action against hepatitis.
AbbVie aiming to steal market share from Gilead